These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15642439)

  • 1. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies.
    Abi-Dargham A; Laruelle M
    Eur Psychiatry; 2005 Jan; 20(1):15-27. PubMed ID: 15642439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of action of novel antipsychotic drugs.
    Meltzer HY
    Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probing targets for antipsychotic drug action with PET and SPET receptor imaging.
    Pilowsky LS
    Nucl Med Commun; 2001 Jul; 22(7):829-33. PubMed ID: 11453058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission.
    Marcus MM; Wiker C; Frånberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):891-903. PubMed ID: 19835668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
    Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
    Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia.
    Abi-Dargham A; Moore H
    Neuroscientist; 2003 Oct; 9(5):404-16. PubMed ID: 14580124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity.
    Sammut S; Bray KE; West AR
    Psychopharmacology (Berl); 2007 Apr; 191(3):793-803. PubMed ID: 17206493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
    Laruelle M; Kegeles LS; Abi-Dargham A
    Ann N Y Acad Sci; 2003 Nov; 1003():138-58. PubMed ID: 14684442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia.
    Kasper S; Tauscher J; Küfferle B; Barnas C; Pezawas L; Quiner S
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 4():83-9. PubMed ID: 10654113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of radioligands in schizophrenia research.
    Sedvall G; Farde L; Hall H; Halldin C; Karlsson P; Nordström AL; Nyberg S; Pauli S
    Clin Neurosci; 1995; 3(2):112-21. PubMed ID: 7583617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
    Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
    Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs.
    Svensson TH
    Brain Res Brain Res Rev; 2000 Mar; 31(2-3):320-9. PubMed ID: 10719159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.
    Yang CR; Chen L
    Neuroscientist; 2005 Oct; 11(5):452-70. PubMed ID: 16151046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schizophrenia: from dopaminergic to glutamatergic interventions.
    Laruelle M
    Curr Opin Pharmacol; 2014 Feb; 14():97-102. PubMed ID: 24524997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.